Collectively, our results established FoxM1 as an indispensible molecular target of Artemisinin in HCC and verified the potential of repurposing Artemisinin, preferably in combination with a FoxM1 inhibitor, as an innovative anticancer therapy for control of HCC. The gene discussed is FOXM1; the disease is hepatocellular carcinoma.